ACET
Adicet Bio Inc.
Company Overview
| Mkt Cap | $98.08M | Price | $8.33 |
| Volume | 90.23K | Change | +0.36% |
| P/E Ratio | -0.8 | Open | $8.44 |
| Revenue | -- | Prev Close | $8.30 |
| Net Income | $-116.8M | 52W Range | $6.01 - $17.44 |
| Div Yield | N/A | Target | $34.83 |
| Overall | 43 | Value | 60 |
| Quality | 31 | Technical | 40 |
No chart data available
About Adicet Bio Inc.
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Latest News
Wedbush Sticks to Its Buy Rating for Adicet Bio (ACET)
Adicet Bio Issues Pre-Funded Warrant in Equity Exchange
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ACET | $8.33 | +0.4% | 90.23K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |